Clinical trials: Urinary
Non-muscle Invasive Bladder Cancer
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.
- Trial name
- NCT07206225
- Testing
- PF-08052667, Sasanlimab, BCG
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 294 people
- Sponsor
- Pfizer
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
- Trial name
- NCT07335484
- Testing
- Axonics External Trial System (ETS)
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- Axonics, Inc.
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
- Trial name
- NCT07725796
- Testing
- UGN-501
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Urothelial Cancer, Metastatic Urothelial Cancer
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
- Conditions
- Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC)
- Trial name
- NCT07869836
- Testing
- T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
- Where
- 2 sites in United States
- Volunteers
- 520 people
- Sponsor
- SystImmune Inc.
Uncomplicated Urinary Tract Infections
A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection
Multicenter, Randomized, Open-label, Active-controlled Study with Blinded Assessor to Evaluate the Safety and Tolerability of Pivmecillinam Hydrochloride versus Nitrofurantoin for the Treatment of Female Pediatric Subjects, 12…
- Trial name
- NCT07871968
- Testing
- Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Alembic Therapeutics
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Bladder Cancer
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
- Trial name
- KEYNOTE-866 (NCT03924856)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 175 sites in United States, Australia and 20 more
- Volunteers
- 907 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Canada and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Urothelial Cancer, Advanced/Metastatic Urothelial Cancer
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to…
- Conditions
- Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
- Trial name
- NCT07421700
- Testing
- PF-08634404, Enfortumab Vedotin
- Where
- 184 sites in United States, Australia and 4 more
- Volunteers
- 132 people
- Sponsor
- Pfizer
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Trial name
- FORAGER-2 (NCT07218380)
- Testing
- Vepugratinib, EV, Pembrolizumab
- Where
- 276 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
ProACT Post-Approval Study
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation.
- Trial name
- NCT03767595
- Testing
- ProACT Adjustable Continence Therapy for Men
- Where
- 14 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Uromedica
Urinary Incontinence, Urinary Incontinence,Stress
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a…
- Trial name
- NCT04248283
- Testing
- Adjustable Continence Therapy for Women (ACT)
- Where
- 8 sites in United States, France
- Volunteers
- 167 people
- Sponsor
- Uromedica
Stress Urinary Incontinence in Women
Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence
The goal of this clinical trial is to evaluate whether a treated umbilical vein allograft is effective in treating stress urinary incontinence in females.
- Trial name
- NCT06678984
- Testing
- with treated umbilical vein allograft, with autologous fascial pubovaginal sling
- Where
- 8 sites in France
- Volunteers
- 96 people
- Sponsor
- TBF Genie Tissulaire
Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Trial name
- ADVANCED-3 (NCT07480356)
- Testing
- TARA-002, Investigator's Choice of Intravesical Chemotherapy
- Where
- 11 sites in United States, Ukraine
- Volunteers
- 284 people
- Sponsor
- Protara Therapeutics
Calculi, Renal, Calculi, Urinary
Modified SOLTIVE Study
This is a study to collect procedural data during the use of the SOLTIVE™ Premium SuperPulsed Laser System in the treatment of bladder, ureteral, and kidney stones and BPH to inform the development of software algorithms.
- Conditions
- Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
- Trial name
- NCT07838077
- Testing
- SOLTIVE Premium SuperPulsed Laser System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Olympus Corporation of the Americas
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Recurrent Urinary Tract Infections in Women
Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women
The goal of this clinical trial is to learn if drug U101 works to prevent recurrent urinary tract infection (rUTI) in women (≥ 20 and < 76 years old) with a medical history.
- Trial name
- U101 (NCT07184827)
- Testing
- U101
- Where
- 18 sites in Taiwan
- Volunteers
- 348 people
- Sponsor
- TCM Biotech International Corp.
Bladder Cancer
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with…
- Trial name
- NCT07232602
- Testing
- MK-3120, EV, Pembrolizumab
- Where
- 17 sites in United States, Chile and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC